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Background: Everolimus-eluting stent (EES) is currently one of the most commonly used second-generation drug-eluting stents in clinical practice. 
There is increasing interest in the comparison of EES versus the first generation DES sirolimus-eluting stent (SES), especially in patients with acute 
myocardial infarction (AMI).
Methods: A total of 2965 AMI patients who underwent percutaneous coronary intervention (PCI) with EES (n=1701), or SES (n=1264) were rerolled 
from Korea Acute Myocardial Infarction Registry (KAMIR). The composite clinical outcomes at 1 year were compared between the 2 groups. Target 
lesion failure (TLF) was defined as the composite of cardiac death, target lesion recurrent nonfatal myocardial infarction (Re-MI), or target lesion 
revascularization (TLR). Total major adverse cardiac events (MACE) included total death, Re-MI, and target vessel revascularization (TVR).
Results: The two groups had similar baseline characteristics. The clinical outcomes at 1 year showed that although the 2 groups did not differ 
significantly in the incidences of cardiac death, Re-MI and TLR, EES group had significantly lower incidences of 1-year total death (5.9% vs 8.3%, 
P=0.012), TVR (1.6% vs 3.2%, P=0.006), TLF (6.1% vs 7.9%, P=0.048), total MACE (8.2% vs 12.6%, P<0.001) and stent thrombosis (0.4% vs 1.1%, 
P=0.013) as compared with SES group. However, after multivariable Cox regression adjusted for baseline confounders, the differences in total death 
[odds ratio (OR) 1.01, 95% confidence interval (CI) 0.76-1.36, P=0.927], TVR (OR 1.01, 95% CI 0.61-1.67, P=0.960), TLF (OR 1.14, 95% CI 0.85-
1.53, P=0.393), total MACE (OR 0.99, 95% CI 0.78-1.26, P=0.944) and stent thrombosis (OR 0.81, 95% CI 0.27-2.43, P=0.712) were no longer 
significant.
Conclusions: The unrestricted use of EES and SES seems to have similar safety and efficacy profiles in the setting of AMI. Further randomized 
studies with larger study population are warranted to get definite conclusions.
